
    
      This is an outpatient, open-label study. After a screening period of up to 4 weeks, all
      eligible subjects will receive 2 doses, 6 weeks apart, of GTL001 Powder reconstituted with
      water for injection. GTL001 will be adjuvanted with Aldara, 5% imiquimod cream, applied to
      the injection site 15 minutes and 24 hours after each vaccination. The follow-up period is 12
      weeks from the first injection. The duration of the study is defined for each subject as the
      date that signed, written informed consent is provided through the last follow-up visit.
      Total duration of subject participation is approximately 16 weeks.
    
  